Clinical application of enoxaparin

Area of Science:

• Pharmacology
• Cardiology
• Vascular Medicine

Background:

• Low-molecular-weight heparins (LMWHs) present significant advantages over unfractionated heparin (UFH).
• LMWHs offer improved pharmacokinetic profiles, including longer half-life and high bioavailability.
• These characteristics allow for predictable anticoagulation without routine monitoring.

Purpose of the Study:

• To review the clinical efficacy and safety of enoxaparin, a specific LMWH.
• To compare enoxaparin with UFH across diverse patient populations and clinical scenarios.
• To evaluate the cost-effectiveness and therapeutic positioning of enoxaparin.

Main Methods:

• Systematic review of clinical studies involving enoxaparin.
• Comparative analysis of enoxaparin versus UFH in surgical and non-surgical patients.
• Assessment of outcomes including venous thromboembolism prevention, bleeding complications, and cardiac events.

Main Results:

• Enoxaparin demonstrates similar efficacy to UFH in general surgery for venous thromboembolism prevention but with better tolerability.
• In cancer, orthopedic, and vascular surgery, enoxaparin shows significantly higher efficacy with comparable bleeding rates.
• Enoxaparin is effective in severe cardiac disease, acute coronary syndromes, and deep vein thrombosis, offering advantages in home administration and cost-effectiveness.
• It is also a safe alternative for electrical cardioversion in atrial fibrillation.

Conclusions:

• Enoxaparin is a versatile and effective anticoagulant with a favorable safety profile compared to UFH.
• Its predictable pharmacokinetics and efficacy make it suitable for both inpatient and outpatient settings.
• Enoxaparin represents a cost-effective therapeutic option, particularly in acute coronary syndromes and for home treatment of deep vein thrombosis.